哮喘和鼻息肉患者的当前和新型生物疗法。
Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.
机构信息
University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA, USA.
出版信息
Otolaryngol Clin North Am. 2024 Apr;57(2):225-242. doi: 10.1016/j.otc.2023.08.006. Epub 2023 Sep 9.
A substantial portion of asthma and nasal polyps (NPs) share a common pathogenesis, which includes type 2-mediated inflammation. Distinct endotypes and phenotypes characterizing asthma and chronic rhinosinusitis have been identified. With emerging evidence describing pathophysiology, novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs.
哮喘和鼻息肉（NPs）的很大一部分具有共同的发病机制，包括 2 型介导的炎症。已经确定了哮喘和慢性鼻-鼻窦炎的不同表型和表型。随着描述病理生理学的新证据的出现，生物单克隆抗体治疗的新靶点已经被开发出来。目前，美国食品和药物管理局批准了六种生物疗法来治疗哮喘，包括奥马珠单抗、美泊利单抗、瑞利珠单抗、贝那利珠单抗、度普利尤单抗和替西珠单抗，其中三种——奥马珠单抗、美泊利单抗和度普利尤单抗——也被批准用于治疗 NPs。
Zotero 插件